ClosetInvestor, But that doesn’t account for
Post# of 148181
Quote:
But that doesn’t account for NP’s silence regarding ongoing CTC and imaging results.
From August 28 CYDY's Conference Call announcement:
Quote:
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
Less than three weeks ago CreatvMicro Tech was invited to tell us about the measurement of CTC and CAMS and the potential of Leronlimab in light of the results obtained.
I would not infer that inviting a company to talk about Oncology measurements is silence, by the contrary. Of course, we will all like to have results of ongoing numbers of the patients that were injected before (how are they progressing). As I posted before even one patient with o CTC or a "small" gain in OS (as his MIL seems to suggest) is huge in this field.
We are talking STOPING metastasis here. With all the implications this entails.